Locations:
Search
The shifting role of cell therapy and steroids in the relapsed/refractory setting
Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists
Addressing rare disease and challenging treatment course in an active young patient
Study shows high rate of hematologic responses, low rate of disease progression
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma
Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population
Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy
Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.
Patient achieves complete remission from aggressive marginal zone lymphoma with liso-cel
Patient with TP53 mutation achieves full response with targeted therapy
Advertisement
Advertisement